Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study.

NCT00332215 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT00332215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00332215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study.
Lead sponsor
University of Minnesota
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2006
Completion date
Not reported
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis